Loading…
This event has ended. View the official site or create your own event → Check it out
This event has ended. Create your own
View analytic
Thursday, May 1 • 12:45pm - 1:45pm
Treatment Considerations for Chronic Myeloid Leukemia (CML) Adult Patients After Multiple Tyrosine Kinase Inhibitor (TKI) Failures

Sign up or log in to save this to your schedule and see who's attending!

With the approval and launch of five oral tyrosine kinase inhibitors (TKIs) and one SQ protein synthesis inhibitor—as well as learnings and improvements in monitoring the disease—chronic myeloid leukemia (CML) has steadily transformed to an ever more chronic disease. This theater presentation will provide an overview of CML that will include the basics of the disease, with a focus on the management of patients in whom at least two TKIs have failed. It will review and discuss a relevant CML patient case and associated course of treatment.

This is a Teva Oncology promotional activity. Seating is on a first-come, first-served basis. Please plan to arrive early to have the best chance at securing your seat. 

Thursday May 1, 2014 12:45pm - 1:45pm
Theater 1, Hall B Anaheim Convention Center, 800 W. Katella Avenue. Anaheim, CA 92802
  • CNE Status No CNE
  • Contact Hours of CNE: N/A